Andrea Corbingi

A case of T-prolymphocytic leukemia harboring RAS mutation

Salvatore Perrone, Giada Pacitto, Alessia Tirnetta, Claudia Mulargia et autres

The text reports the clinical case of a 61-year-old woman with a long history of generalized pruritus who was eventually diagnosed with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive T-cell lymphoproliferative disorder. At presentation, the patient had fever, skin lesions, lymphocytosis, …

it (code pays fourni par la source)

Asciminib and pulsed ATRA as post-remission therapy in T315I mutated PML-RARA-positive blast crisis of chronic myeloid leukemia

Roberta Mazzarella, Laura Cicconi, Salvatore Perrone, Maria Domenica Divona et autres

Promyelocytic blast crisis (BC) of CML is an extremely rare event, with only seven cases described as arising during therapy with TKIs. We present a 68-year-old male who developed promyelocytic blast crisis 12 months after CML diagnosis and start of Imatinib therapy, …

it (code pays fourni par la source)

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy

Salvatore Perrone, Andrea Corbingi, Calogero Vetro, Fanny Erika Palumbo et autres

Acute myeloid leukemia (AML), especially therapy-related (t-AML) or secondary AML (s-AML), presents complex therapeutic challenges. CPX-351, a liposomal formulation of cytarabine and daunorubicin, has demonstrated superior outcomes compared to standard 7 + 3 chemotherapy. However, optimal post-remission strategies are debated. This retrospective …

it (code pays fourni par la source)

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351

Raffaele Palmieri, Fabio Guolo, Luana Fianchi, Felicetto Ferrara et autres

CPX-351, a novel liposomal formulation of cytarabine and daunorubicin, represents the standard of care in fit patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML). Considering its better safety profile than conventional intensive chemotherapy, we investigated its cost-to-benefit …

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Matteo Molica, Gema Miralles, Richard Dillon, Mario Annunziata et autres

Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) following ≥ 1 prior line of therapy. However, data on its effectiveness in later-line settings is limited. We conducted a multicenter, retrospective …

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351

Raffaele Palmieri, Fabio Guolo, Luana Fianchi, Felicetto Ferrara et autres

ABSTRACT: CPX-351, a novel liposomal formulation of cytarabine and daunorubicin, represents the standard of care in fit patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML). Considering its better safety profile than conventional intensive chemotherapy, we investigated its …

it, us (code pays fourni par la source)

Effectiveness of Gilteritinib Beyond Second‐Line Therapy in Relapsed/Refractory FLT3 ‐Mutated Acute Myeloid Leukemia: A Real‐World Multicenter Study of 171 Patients

Matteo Molica, Gema Miralles, Richard Dillon, Mario Annunziata et autres

Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) following ≥ 1 prior line of therapy. However, data on its effectiveness in later-line settings is limited. We conducted a multicenter, retrospective …

es, gb, it, tr (code pays fourni par la source)

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Elisabetta Todisco, Ivana Lotesoriere, Federico Lussana, Valentina Mancini et autres

Abstract CPX-351 has been approved for Acute Myeloid Leukemia (AML) with myelodysplasia related changes (AML-MRC) and therapy-related (t-AML) induction. The likelihood of TP53 mutations (TP53m) in this setting is 20-35% but, considering the many variables of TP53m topography and configuration, the assessment …

it, us, pt, ca (code pays fourni par la source)

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Matteo Molica, Gema Miralles, Richard Dillon, Mario Annunziata et autres

Abstract Background: Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) following at least one prior line of therapy. However, evidence regarding its efficacy in later-line settings remains limited. Methods: We …

it, es, gb, tr (code pays fourni par la source)

A landscape of genetic heterogeneity in germline predisposition to familial chronic lymphocytic leukemia

Luca Laurenti, Eugenio Sangiorgi, Idanna Innocenti, Alberto Fresa et autres

it, jp, br, de (code pays fourni par la source)

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study

Alberto Fresa, Idanna Innocenti, Annamaria Tomasso, Candida Vitale et autres

ABSTRACT: Familial chronic lymphocytic leukemia (CLL) constitutes 5% to 7% of CLL and has previously shown a more aggressive pattern of evolution than sporadic CLL, even if no difference in overall survival (OS) has been observed. This multicenter case-control study aimed to …

it, jp, de (code pays fourni par la source)

The role of the immune system in progressive multifocal leukoencephalopathy: a comparative analysis of two cases following autologous and allogeneic hematopoietic stem cell transplantation

Biancamaria Mandelli, Roberta Mazzarella, Andrea Corbingi, Elettra Ortu La Barbera et autres

Progressive multifocal leukoencephalopathy (PML) is a rare, subacute demyelinating disorder of the central nervous system (CNS) caused by the JCV. In immunosuppressed hosts, PML is caused by reactivation of a latent infection rather than primary exposure. Hematological patients, particularly post-transplant, presenting with …

it (code pays fourni par la source)